Skip to content
The Policy VaultThe Policy Vault

Vanflyta (quizartinib tablets − Daiichi Sankyo) — Cigna

Myeloid or Lymphoid Neoplasms with Eosinophilia and FLT3 Rearrangement

Initial criteria

  • Patient is age ≥ 18 years
  • Patient has eosinophilia
  • The tumor has an FLT3 rearrangement

Approval duration

1 year